P4
In a recent report, aspirin (ASA) inhibited I-κB kinase beta in vitro; however, in vivo relevance has not been shown. We previously showed that NF-κB activation and inflammation are crucial role in the pathogenesis of Ang II-induced vasculopathy. We now tested the hypothesis that ASA inhibits NF-κB and ameliorates renal and cardiac end-organ damage. dTGR feature hypertension, renal and cardiac damage and die at 7 weeks. We treated rats chronically with ASA (600 and 25 mg/kg/d ip). Only ASA 600 prevented mortality, while untreated dTGR and ASA 25 showed mortality >50% at 7 weeks. ASA 600 reduced cardiac hypertrophy (4.0±0.2 vs. 5.7±0.2 mg/g, p<0.001) compared to dTGR. Blood pressure levels in ASA 600 were slightly, but not significantly lower (158±8 vs. 182±8 mm Hg, p=0.2). In contrast, ASA 600 reduced albuminuria by 85 % (p<0.01) and perivascular fibrosis, while ASA 25 had no effect on cardiac and renal damage. ASA 600 inhibited renal I-κB kinase activity and NF-κB DNA binding activity, which were increased in dTGR. Immunostaing of the activated p65 NF-κB subunit was increased in the endothelium, smooth muscles cells, infiltrated cells, glomeruli, and tubules of dTGR and markedly reduced by ASA 600. ASA 600 also reduced immunostaining of NF-κB-regulated genes laminin, ICAM-1, and IL-6. Monocyte infiltration was increased in dTGR hearts and kidneys and reduced by ASA 600, and not by ASA 25. These results demonstrate that high-dose ASA inhibits NF-κB, suppresses inflammation, and protects against ANG II-induced end-organ damage. The data underscore the role of inflammation and identify a novel drug target in this model.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.